Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint

Dow Jones

2024/12/21

By Katherine Hamilton

Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance.

The stock lost more than half its value, falling to about 91 cents midday Friday and hitting a 52-week low.

Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels.

While varices occurred 43% less when patients took belapectin, the composite endpoint wasn't statistically significant and there didn't appear to be increased efficacy when patients received a higher dose, the company said.

The company is performing further analysis on the data from the trial and anticipates having additional data in early 2025, at which point it will provide clinical updates and determine next steps for the treatment's development, it said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

December 20, 2024 14:44 ET (19:44 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2493473245"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2493473245\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2493473245?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-21 03:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493473245","market":"sh","top_or_hot":-1,"title":"Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. \n</p>\n<p>\n  The stock lost more than half its value, falling to about 91 cents midday Friday and hitting a 52-week low. \n</p>\n<p>\n  Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels. \n</p>\n<p>\n  While varices occurred 43% less when patients took belapectin, the composite endpoint wasn't statistically significant and there didn't appear to be increased efficacy when patients received a higher dose, the company said. \n</p>\n<p>\n  The company is performing further analysis on the data from the trial and anticipates having additional data in early 2025, at which point it will provide clinical updates and determine next steps for the treatment's development, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 14:44 ET (19:44 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGalectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-12-21 03:44</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre>\n \n</pre>\n<p>\n  Galectin <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. \n</p>\n<p>\n  The stock lost more than half its value, falling to about 91 cents midday Friday and hitting a 52-week low. \n</p>\n<p>\n  Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels. \n</p>\n<p>\n  While varices occurred 43% less when patients took belapectin, the composite endpoint wasn't statistically significant and there didn't appear to be increased efficacy when patients received a higher dose, the company said. \n</p>\n<p>\n  The company is performing further analysis on the data from the trial and anticipates having additional data in early 2025, at which point it will provide clinical updates and determine next steps for the treatment's development, it said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 20, 2024 14:44 ET (19:44 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2493473245","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493473245","pubTimestamp":1734723840,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance.The stock lost more than half its value, falling to about 91 cents midday Friday and hitting a 52-week low.Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels.While varices occurred 43% less when patients took belapectin, the composite endpoint wasn't statistically significant and there didn't appear to be increased efficacy when patients received a higher dose, the company said.The company is performing further analysis on the data from the trial and anticipates having additional data in early 2025, at which point it will provide clinical updates and determine next steps for the treatment's development, it said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GALT":"Galectin Therapeutics Inc"},"translate_title":"治疗未达到试验终点后，Galectin Therapeutics股价下跌54%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GALT":1},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  Galectin Therapeutics shares fell after it said the endpoint of a liver-disease treatment trial didn't meet statistical significance. \n\n\n  The stock lost more than half its value, falling to about 91 cents midday Friday and hitting a 52-week low. \n\n\n  Galectin's said it hoped that the therapy, called belapectin, would prevent varices, which are abnormally dilated blood vessels. \n\n\n  While varices occurred 43% less when patients took belapectin, the composite endpoint wasn't statistically significant and there didn't appear to be increased efficacy when patients received a higher dose, the company said. \n\n\n  The company is performing further analysis on the data from the trial and anticipates having additional data in early 2025, at which point it will provide clinical updates and determine next steps for the treatment's development, it said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 20, 2024 14:44 ET (19:44 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}